Highlights from the last conference call
We continue to make progress on our reimburse with success in central areas: first, we are partnering with hospitals to jointly fight and denial of insurance claims for L-Dex testing. In several key markets, we are obtaining prior authorizations from these insurance companies for testing of patients for up to a year; two, we are aggressively fighting all denied claim by payers with the hospitals we're partnering with. In 2 cases, we've moved the appeal process to the third and final appeal, and we won both cases. That was background. A third appeal is reviewed by an outside independent group of physicians that the insurance company has to pay for. If an insurance company loses a third appeal, they are heavily fined by the insurance agencies. In both cases, the insurance companies are now providing routine prior authorizations for patients that show medical necessity. So obviously, a big win for us.
A major health network has approached us to discuss covering L-Dex test for all breast cancer patients, while they undergo a review of our technology and evaluate our ability to reduce patient costs. So again, a very exciting turn of events for us. And these are all very important developments that will bolster the meta-analysis and will be bolstered with the met analysis as well as the upcoming preventive trial publication.
The NCCN, if the PREVENT trial show statistical significance, we expect one or more nationally recognized institutions will submit the PREVENT trial data and request inclusion of L-Dex in the guidelines.
For heart failure. We expect to expand our commercial footprint in the coming months as well as establish pilot programs in key heart failure centers. We continue to work with the FDA on the removal of our contraindications for implantable pacing devices as well as the fibrillates.
I could also tell you there's 28 NCCN centers. So these are very prestigious cancer centers in the U.S., and we have 20 of them currently using our device.
Well, we've said our addressable market is north of $1 billion. And I would say that if we had all the insurance companies paying and we didn't have any more hurdles, I would say that, that would be a realistic long-term prospect for the company. But again, I think it's going to take us a while to get there. I think the other thing you have to sort to understand is this new platform we've developed was to go after more than lymphedema. We already have additional claims that we have, additional indications from the FDA that we're now starting to add on the device so we can become a bigger player in the oncology space. So we really see lymphedema as our foot in the door. And we have a number of accounts who are already exploring our ability to test fluid for hydration, our ability to provide them accurate information, on-body composition, so on and so forth. So I would tell you this. I would say our opportunity for the short to medium-term is lymphedema, the need in the long-term is more of the oncology type.
Regards
Bloky
Expand
